Today's remind-it says it all:
"The EMERALD data demonstrated that OMONTYS administered once a month has a similar efficacy and cardiovascular safety profile when compared to epoetin administered one-to-three times weekly."
I'm holding through next sales report, I guess 1/4 more weeks.
Big holders are still on their positions.
So am I.
No, I didn't. That's because I'm on my free shares... here's near the point where I sold half months ago.
But this is my personal path. Fact is I couldn't bear no more the stress, so decided to follow he safest way.
But this is surely a gift, being allowed to buy at these prices.
Just read again what we already know about the drug: "Omonty administered 1-month has same efficacy and safety compared to administered one-to-three times weekly".
It's a matter of time before Affy conquer the market.
Today, Amgen sales report did bash AFFY stock also.
Just read it (it's on google).
They say Omonty didn't affect Epo's market...... yes, sure. ***But their clock is still locked on preliminary sales report after 2 months of Omonty****.